LifePoint soars on FDA medical markets nod
This article was originally published in Clinica
LifePoint saw is stock price surge last week, after revealing that the US FDA has given it the all-clear to expand sales of its saliva-based, on-site test system for detecting the opiates morphine and heroin to medical markets. The firm's shares rose around 40% during trading on Dec 1 when the news was announced.
You may also be interested in...
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”
The Onyx One Clear study, evaluating the Resolute Onyx drug-eluting stent in high bleeding risk patients, met its primary endpoint at the one-year follow up.